Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial

Abstract

Thrombopoietin receptor agonists (TPO-RAs) play a crucial role in stimulating thrombopoiesis. However, conventional meta-analyses have shown inconsistent results regarding the efficacy of thrombopoietin receptor agonists versus placebo. Therefore, we performed a network meta-analysis to assess the effects of five TPO-RAs via indirect comparison. For this network meta-analysis, we considered randomized trials that included any of the following interventions: avatrombopag, lusutrombopag, eltrombopag, romiplostim, recombinant human thrombopoietin (rhTPO). We searched the Medline, PubMed, Embase, the Cochrane Library, and Web of Science databases for randomized controlled clinical trials from inception to January 31, 2021. We use randomized controlled clinical trials of TPO-RAs for treatment of immune thrombocytopenia in adults. The primary outcome was the number of patients achieving platelet response which was defined as the achievement of a platelet count of more than 30 or 50 cells × 109/L in the absence of rescue therapy, and the secondary outcome was the therapy-related serious adverse events and incidence of bleeding episodes. To obtain the estimates of efficacy and safety outcomes, we performed a random-effects network meta-analysis. These estimates were presented as odds ratios with 95% confidence intervals. We use surface under the cumulative ranking probabilities to rank the comparative effects and safety of all drugs against the placebo. In total, 2,207 patients were analyzed in 20 clinical trials. All preparations improved the point estimates of platelet response when compared with the placebo. Avatrombopag and lusutrombopag had the best platelet response compared to the placebo, the former had a non-significant advantage compared to the latter [odds ratio (OR) = 1.91 (95% confidence interval: 0.52, 7.05)]. The treatments were better than eltrombopag, romiplostim, rituximab, and rhTPO + rituximab, with corresponding ORs of 3.10 (1.01, 9.51), 9.96 (2.29, 43.29), 33.09 (8.76, 125.02), and 21.31 (3.78, 119.98) for avatrombopag and 1.62 (0.63, 4.17), 5.21 (1.54, 17.62), 17.34 (5.15, 58.36), and 11.16 (2.16, 57.62) for lusutrombopag. Regarding bleeding, the placebo group had the highest probability of bleeding, whereas lusutrombopag had the lowest risk of bleeding when compared to the placebo. Adverse events were slightly higher in patients receiving rituximab than in those receiving placebo or other treatments. Overall, this meta-analysis showed that avatrombopag may yield the highest efficacy because it has the most favorable balance of benefits and acceptability.

Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia

“…The standard treatment of AAT has not been defined, and the management is often thorny because of their refractoriness to possible treatment choices, including immunosuppressive therapy, rituximab, interleukin-11, recombinant human thrombopoietin (rh-TPO) and even some thrombopoietin receptor agonists (TPO-RAs). As a newly FDA approved TPO-RA for immune ITP, avatrombopag promotes platelet production by stimulating TPO receptor (c-Mpl) with high efficacy and safety (Deng et al, 2021;Gilreath et al, 2021). However, little is known about its effects in the treatment of AAT, especially anti-PD-1/PD-L1 antibody-induced AAT.…”

Transjuguläre Nierenbiopsie

“…In den vergangenen Jahren haben sich hierzu, insbesondere vor dem Hintergrund der Kosten und der Verfügbarkeit, patientenspezifische Vorgehensweisen entwickelt. Diesbezüglich ist im Besonderen die Entwicklung der Thrombopoietin-Rezeptor-Agonisten abzuwarten [5].…”

Individualized Management of Coagulopathy in Patients with End-Stage Liver Disease

“…The theoretical advantage compared to platelet transfusion is a lower transfusion-associated risk caused by a lower immunological burden. However, depending on the product used, the effectiveness may be highly variable [ 86 ]. Larger studies that could describe the side effect profile of TPO-R agonists with ESLD patients are currently lacking.…”